NEWS

logo.gif (1594 bytes)

NEWS

Monsanto Company and Rosetta Inpharmatics to collaborate on crop discovery program
St. Louis, Missouri and Kirkland, Washington
November 28, 2000

Monsanto Company (NYSE: MON) and Rosetta Inpharmatics, Inc. (Nasdaq: RSTA - news) today announced that they have converted their existing pilot agreement to a full-scale, three-year collaboration. This collaboration will apply Rosetta's cutting edge informational genomics technologies to the development of better crops.

Under terms of the agreement, Monsanto has committed to pay Rosetta $15 million over a
three-year period for the delivery of a substantial body of gene expression information to
Monsanto. In addition, Rosetta has the potential to receive future payments including royalties,
associated with the development of commercial products that incorporate discoveries from the
collaboration.

"We're delighted to be expanding our relationship with Rosetta and embarking on this innovative
approach to high-throughput discovery,'' said Chris Burnley, Vice President for Genomics
Strategy and Alliances at Monsanto. "Rosetta's capabilities in the area of gene expression
analysis and bioinformatics will be a powerful complement to our existing genomics network. By
combining our sequence portfolio with Rosetta's expertise, we are creating a unique capability to
further understand gene expression in crops.''

"Monsanto is widely recognized as a world leader in crop genomics and we are delighted to be
extending our relationship with them,'' added Stephen Friend, M.D., Ph.D., President and Chief
Executive Officer of Rosetta Inpharmatics. "Monsanto's commitment to this extended partnership
further validates Rosetta's capabilities in informational genomics, the integration of genomic and
informatics technologies.''

The collaboration is exclusive for the family of crops that includes corn, rice and wheat. Among
other activities, Rosetta will create a large database of gene expression profiles, and will apply
existing and newly developed computational tools to data analysis.

Monsanto Company, an 85 percent owned subsidiary of Pharmacia Corporation (NYSE: PHA -
news), is a leading global provider of technology-based solutions and agricultural products that
improve farm productivity and food quality. For more information on Monsanto, see:
www.monsanto.com .

Rosetta Inpharmatics offers informational genomics solutions. By combining the power of
informatics and genomics, Rosetta has created a proprietary platform that accelerates and
enhances the drug discovery process for pharmaceutical and biotechnology companies, and
improves agricultural products. Rosetta Inpharmatics' approach converts the rapidly growing
amount of gene expression data, or information about a gene's activity, into organized, statistically driven, information-based results.

Rosetta Inpharmatics provides a proprietary gene expression profiling platform, consisting of
hardware and software products that uses gene expression profiles to provide seamless solutions
for efficient, cost- effective and powerful discovery programs. Rosetta Inpharmatics' technology
builds a critical mass of coherent gene expression data collected from DNA microarrays, which
are comprised of DNA fragments attached to glass slides in a grid-like pattern. This platform
provides comprehensive, simultaneous descriptions of a compound's effect on all relevant targets
within a cell.

Company news release
N3168

.0

Copyright © 2000 SeedQuest - All rights reserved